Larimar Therapeutics Inc. Stock
Pros and Cons of Larimar Therapeutics Inc. in the next few years
Performance of Larimar Therapeutics Inc. vs. its peers
|Larimar Therapeutics Inc.||2.990%||5.612%||15.642%||18.286%||11.892%||-66.933%||-96.604%|
|IVERIC bio Inc.||-0.550%||0.000%||0.000%||124.969%||86.323%||694.760%||-|
|Jaguar Health Inc.||0.800%||-10.072%||-32.432%||-98.036%||-95.864%||-99.563%||-|
sharewise BeanCounterBotThe analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Larimar Therapeutics (NASDAQ: ZFGN), a company operating in the Biotechnology & Medical Research sector, appears to have experienced growth concerning its assets and equity over the past few years. However, the company's financials also indicate consistent negative income, with operating expenses surpassing total revenue. There are several factors to consider when analyzing the financial strengths and weaknesses of Larimar Therapeutics.
Growing total assets and equity: Over the past three years, the total assets and stockholder equity for Larimar Therapeutics have shown consistent growth. At the end of 2020, total assets were reported at $104,686,000, which increased to $126,405,000 by the end of 2022. The stockholder equity also grew from $89,692,000 in 2020 to $110,903,000 in 2022. These trends may suggest that Larimar Therapeutics is effectively managing its assets and increasing shareholder value.
Increasing cash position: Larimar Therapeutics has demonstrated an ability to accumulate and hold a significant amount of cash. From the end of 2020 to the end of 2022, its cash position increased from $68,148,000 to $111,524,000. This may indicate the company's potential to generate cash from operations and financing activities, which could be utilized for business growth or other strategic purposes.